2025 NRDL turned out to be one of the most competitive to date, while the C-list emerging as an alternative pathway with distinct trade-offs. With the unveiling of new China guidelines for pharmacoeconomic evaluations and the pilot for comparator pre-communication, there will be more dynamic developments down the road.
Join our upcoming webinar for China NRDL 2026 outlook.
The webinar will cover:
- Latest NRDL trends and outlook
- Implications from the latest policies and guidelines
- Success factors and key takeaways
This event is free of charge. Don’t miss this opportunity to gain valuable insights into NRDL 2026 trends and position yourself for success in the upcoming cycle.
